60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
60 Degrees Pharmaceuticals reported Q1 2026 revenue of $162,000, a 1% decline year-over-year, with a net loss of $2.21 million ($1.28 per share). Operating expenses rose to $2.17 million from $2.09 million in the prior year, while gross profit contracted to $76,000 from $90,000.
Key figures
- Revenue
- 162000
- Revenue Yoy
- -1%
- Net loss
- 2210000
- Gross profit
- 76000
- Operating expenses
- 2170000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.